$ADVM finance.yahoo.com/news/adve... "In both cohorts combined, 10 of 12 (83%) patients remain rescue-injection-free. For these patients: Vision was generally maintained as demonstrated by stable mean best corrected visual acuity (BCVA) compared to baseline. Retinal anatomy improvements were achieved and maintained as demonstrated by mean central subfield thickness (CST) compared to baseline. ADVM-022 continues to demonstrate a favorable safety profile and be well tolerated with no drug-related or procedure-related serious adverse events (SAEs), no drug-related systemic adverse events, and no adverse events meeting the criteria for dose-limiting toxicities (DLTs). ADVM-022-related adverse events (AEs) have been mild (71%) to moderate (29%). Low-grade ocular inflammation was commonly reported and was responsive to steroid eye drops."